LIVZON PHARMA (01513) announced that its Board of Directors held the 28th meeting of the 11th session on November 10, 2025, approving the proposal to nominate Ms. Wang Zhiyao as an independent non-executive director candidate. The resolution remains subject to approval at the company's shareholders' meeting. If approved, her term will commence from the date of shareholders' approval until the expiration of the 11th Board term.

At the time of issuing the notice for the 2025 first extraordinary general meeting, Ms. Wang had not yet obtained the independent director training certification. In compliance with Shenzhen Stock Exchange (SZSE) regulations, she submitted a written commitment to complete the required pre-appointment training and obtain SZSE-recognized certification.

The company recently received confirmation that Ms. Wang has successfully completed the latest online pre-appointment training for independent directors and obtained the SZSE-accredited certification. Additionally, her qualifications and independence as an independent director candidate have been reviewed and approved by the SZSE without objection.